Antidepressant-like effect of coadministration of sulpiride and fluvoxamine in mice

被引:16
作者
Ago, Y
Harasawa, T
Itoh, S
Nakamura, S
Baba, A
Matsuda, T [1 ]
机构
[1] Osaka Univ, Grad Sch Pharmaceut Sci, Lab Med Pharmacol, Osaka, Japan
[2] Osaka Univ, Grad Sch Pharmaceut Sci, Lab Mol Neuropharmacol, Osaka, Japan
关键词
tail suspension test; sulpiride; fluvoxamine; antidepressant; WAY100635;
D O I
10.1016/j.ejphar.2005.08.011
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We have recently reported that coadministration of sulpiride, an antipsychotic drug, and fluvoxamine, a selective serotonin (5-HT) reuptake inhibitor, selectively increases in vivo dopamine release in the prefrontal cortex. This study examined the effects of coadministration of these drugs on duration of immobility in the tail suspension test using mice. Neither sulpiride (3 or 10 mg/kg) nor fluvoxamine (10 or 20 mg/kg) alone affected immobility time, whereas coadministration significantly reduced immobility time. WAY100635, a 5-HT1A receptor antagonist, did not affect the effects of sulpiride and fluvoxamine coadministration, but reduced immobility time in combination with fluvoxamine (20 mg/kg). A high dose of fluvoxamine alone (60 mg/kg) also reduced immobility time. These results suggest that the antidepressant-like effects of fluvoxamine in combination with sulpiride or WAY100635 in the tail suspension test are mediated by the activation of dopamine or 5-HT systems, respectively. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:86 / 90
页数:5
相关论文
共 35 条
[1]   Regulation by 5-HT1A receptors of the in vivo release of 5-HT and DA in mouse frontal cortex [J].
Ago, Y ;
Koyama, Y ;
Baba, A ;
Matsuda, T .
NEUROPHARMACOLOGY, 2003, 45 (08) :1050-1056
[2]   Sulpiride in combination with fluvoxamine increases in vivo dopamine release selectively in rat prefrontal cortex [J].
Ago, Y ;
Nakamura, S ;
Baba, A ;
Matsuda, T .
NEUROPSYCHOPHARMACOLOGY, 2005, 30 (01) :43-51
[3]   How does pindolol improve antidepressant action? [J].
Artigas, F ;
Celada, P ;
Laruelle, M ;
Adell, A .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2001, 22 (05) :224-228
[4]   Amitriptyline v. the rest:: still the leading antidepressant after 40 years of randomised controlled trials [J].
Barbui, C ;
Hotopf, M .
BRITISH JOURNAL OF PSYCHIATRY, 2001, 178 :129-144
[5]  
BENKERT O, 1984, ACTA PSYCHIAT SCAND, V311, P43
[6]  
Blier P, 1998, J CLIN PSYCHIAT, V59, P16
[7]   Evidence for accelerated desensitisation of 5-HT2C receptors following combined treatment with fluoxetine and the 5-HT1A receptor antagonist, WAY 100,635, in the rat [J].
Bristow, LJ ;
O'Connor, D ;
Watts, R ;
Duxon, MS ;
Hutson, PH .
NEUROPHARMACOLOGY, 2000, 39 (07) :1222-1236
[8]   Blockade of pre- and post-synaptic 5-HT1A receptors does not modify the effect of fluoxetine or 5-hydroxytryptophan on ethanol and food intake in rats [J].
Ciccocioppo, R ;
Panocka, I ;
Polidori, C ;
Dourish, CT ;
Massi, M .
PSYCHOPHARMACOLOGY, 1997, 134 (01) :55-63
[9]   The serotonin-1A receptor antagonist WAY-100635 modifies fluoxetine's antidepressant-like profile on the differential reinforcement of low rates 72-s schedule in rats [J].
Cousins, MS ;
Seiden, LS .
PSYCHOPHARMACOLOGY, 2000, 148 (04) :438-442
[10]   Influence of anxiolytic drugs on the effects of specific serotonin reuptake inhibitors in the forced swimming test in mice [J].
DaRocha, MA ;
Puech, AJ ;
Thiebot, MH .
JOURNAL OF PSYCHOPHARMACOLOGY, 1997, 11 (03) :211-218